Althea Technologies, Inc. Chosen by Quintessence Biosciences, Inc. to Produce Lead Protein Oncology Drug
2/5/2008 10:16:56 AM
SAN DIEGO, CA--(Marketwire - February 05, 2008) - Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has been awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm's first drug candidate. The drug candidate QBI-139 is effective in cancer models against a broad range of solid tumors. Quintessence plans to file an investigational new drug application (IND) for QBI-139 with the U.S. Food and Drug Administration (FDA) in the first quarter of 2008. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.